1. Introduction {#s0005}
===============

Alzheimer\'s disease (AD) is the most common cause of cognitive impairment in older persons. In recent years, AD has been conceptualized as a progressive sequence of pathophysiological changes that include the extracellular accumulation of amyloid-β (Aβ), tau-mediated neuronal dysfunction/death and brain atrophy that correspond roughly to cognitively unimpaired, mild cognitive impairment (MCI) and dementia stages ([@bb0090], [@bb0095]).

Brain imaging measurements have been used to detect and track Aβ, tau, and neurodegenerative features of AD in the preclinical (cognitively unimpaired), MCI and dementia stages. The best established examples include PET measurements of fibrillar Aβ deposition, PET measurements of paired helical filament (PHF) tau deposition, MRI measurements of hippocampal and whole brain atrophy, and fluorodeoxyglucose PET measurements of regional cerebral metabolic rate for glucose (rCMRgl) decline in brain regions preferentially affected by AD ([@bb0075]; [@bb0180]; [@bb0205]). In the most recent conceptualization ([@bb0095]), biomarker evidence of amyloid-β (Aβ) pathology reflects "AD pathophysiological change", biomarker evidence of both amyloid-β and tau pathology reflects "AD", and individuals can also be characterized in terms of the evidence of neurodegenerative disease changes that may include rCMRgl declines and brain atrophy (i.e., "AT(N)" research criteria for AD; [@bb0095])).

AD and related disorders are associated with distinctive MRI and FDG PET patterns of neurodegeneration. Some neurodegenerative diseases appear to begin with or are characterized by asymmetric patterns of neurodegeneration (e.g., Parkinson\'s Disease (PD) and Primary Progressive Aphasia (PPA), ([@bb0020]; [@bb0050]). While AD has been characterized by bilateral neurodegenerative disease changes in medial temporal and heteromodal sensory association areas, several neuroimaging studies have suggested a pronunciation of the left hemisphere with respect to amyloid deposition ([@bb0175]) gray matter atrophy ([@bb0100]; [@bb0210]; [@bb0230], [@bb0235]), cerebral perfusion and metabolism ([@bb0040]; [@bb0120]; [@bb0240]) in persons with AD. Whereas many of these findings (particularly from studies of brain metabolism) have been cross-sectional, we sought to investigate the possibility that amyloid-β positive (Aβ+) persons might demonstrate asymmetric left lateralized longitudinal patterns of neurodegeneration, especially during the earlier clinical stages of AD. To address this possibility we compared longitudinal patterns of rCMRgl declines in Aβ + probable AD dementia, MCI and an amyloid-β negative (Aβ-) cognitively unimpaired control group from the AD Neuroimaging Initiative (ADNI).

2. Subjects and methods {#s0010}
=======================

2.1. Subjects {#s0015}
-------------

Participant data for this study were drawn from the ADNI dataset, an ongoing longitudinal study (currently ADNI-3) devoted to the establishment of biological and neuroimaging biomarkers of MCI and Alzheimer\'s disease. Detailed information on participant recruitment, inclusion- and exclusion criteria are provided on the ADNI website ([www.adni-info.org/index.php](http://www.adni-info.org/index.php){#ir0015}). In order to maximise the sensitivity of our analyses we only included amyloid-β negative (Aβ-) cognitively unimpaired control subjects (CU) based on CSF measures (threshold\>192) or florbetapir PET (threshold\<1.18) with cerebellum reference region, thereby optimally avoiding the inclusion of subjects with preclinical and asymptomatic stages of AD. Similarly only amyloid-β positive (Aβ+) MCI and AD patients were included, thus avoiding misclassification of patients and maximising the probability of AD pathology being the underlying cause of cognitive impairment. In total, we selected a sample of *n* = 167 subjects, based on availability of longitudinal FDG PET scans and information on amyloid pathology, resulting in a sample of 51 Aβ + subjects with AD dementia, 76 Aβ + subjects with MCI, and 40 Aβ- CU. In the following, we will refer to MCI-AD and dementia-AD for MCI and dementia subjects with evidence of AD pathology.

2.2. Clinical evaluation {#s0020}
------------------------

For each subject, cognitive function was evaluated at each visit (for details please see [www.adni-info.org](http://www.adni-info.org){#ir0020}). Measures of cognitive function included - next to others - the Auditory Verbal Learning Test \[AVLT; ([@bb0185])\] Total and Long-Term Memory (LTM) scores, CDR sum of boxes (CDR-SOB; ([@bb0140])), MMSE ([@bb0035]), Category Fluency (animals) ([@bb0195]) and the modified AD Assessment Scale-Cognitive Subscale (i.e. ADAS-Cog 11/13; [@bb0135]; [@bb0200]). Delta values were calculated for each test and participant. In addition subdomains and individual subitems of the ADAS-cog 13 were analyzed with the goal to further evaluate baseline impairment and subsequent decline of specific cognitive domains. Subitems of the ADAS-cog 13 comprise the following cognitive subdomains: Memory and new learning (i.e. Word Recall, Orientation, Word Recognition, Delayed Word Recall, Recall Instructions), language (i.e. Commands, Naming, Spoken Language, Word Finding, Comprehension), praxis (i.e. Construction, Ideational Praxis) and processing speed (i.e. Number Cancellation) with higher scores indicating worse performance. For the item "Number Cancellation" data points were missing for *N* = 5 subjects (*N* = 4 dementia-AD; *N* = 1 CU). Since individual subitems of the ADAS-cog 13 differ with respect to the maximum possible value, results were illustrated as percentage of the maximum possible scores. Non-imaging data were analyzed using ANOVA or Chi Square whenever applicable. For post-hoc between group comparisons Duncan\'s multiple range test was applied. Results are reported at alpha 0.05 uncorrected.

2.3. Imaging procedures {#s0025}
-----------------------

Longitudinal imaging data from different participating sites were subjected to a standardized protocol (<http://www.loni.ucla.edu/ADNI/Data/ADNI_Data.shtml>) of measured-attenuation correction and specific reconstruction algorithms in order to account for site specific differences. These preprocessing steps were performed by the ADNI PET Coordinating Center at the University of Michigan made available for download at the LONI ADNI website. After download of PET images additional pre-processing steps were performed using SPM5 (<http://www.fil.ion.ucl.ac.uk/spm>), including deformation into a standard space of the Talairach atlas and spatial smoothing with a 3-dimensional Gaussian filter with 8 mm full width at half maximum. Next, subtraction images of the FDG scans scaled by the global counts were calculated (i.e. baseline/global_at_baseline -- followup/global_at_followup) for characterization and comparisons of 24-month rCMRgl declines.

To test the hypothesis of lateralized longitudinal declines of rCMRgl declines we used SPM8 ([www.fil.ion.ucl.ac.uk](http://www.fil.ion.ucl.ac.uk){#ir0030}) and the LI-toolbox ([@bb0255]). First, SPM8 was used for voxel-based analyses of rCMRgl declines by applying either two-sample *t*-test for group comparisons or one sample *t*-tests for within group analyses to the above mentioned subtraction images. In addition, post-hoc regression analyses were performed to investigate associations of cognitive decline \[(i.e. ADAS-cog 13 and Category Fluency (animals)\] with rCMRgl declines in dementia-AD and MCI-AD subjects. Then, SPM derived T-maps were analyzed with the LI-toolbox by calculating an overall weighted bootstrapped lateralization index (LI) for the unthresholded maps. This approach combines the commonly used lateralization eq. (LI = (left-right)/(left+right)) with adaptive thresholding and automated bootstrapping algorithms to minimize the impact of outliers. For our analyses we furthermore used an inclusive standard gray matter mask and an additional exclusive mask (i.e. midline +/− 5 mm) as provided by the LI-toolbox, in order to reduce noise related artifacts. For the calculated LI weighted means (LIwm), negative values indicate right hemispheric lateralization and positive values indicate left hemispheric lateralization. Based on the LIwm, lateralization was classified as either absent (LIwm −0.25 to 0.25), weak (LIwm −0.25 to −0.50 and 0.25 to 0.50) or strong (LIwm \<−0.50 and \> 0.50) (e.g. [@bb0025]). Importantly, this approach largely avoids the introduction of arbitrary thresholds and strongly reduces the impact of potential outliers.

The main goal of this study was to statistically quantify lateralization of longitudinal rCMRgl declines, by using a global index that provides information free of the type-1 error due to multiple comparisons, via the above mentioned analytical approach (i.e. the bootstrapped lateralization indices for unthresholded maps). Since the introduction of conservative thresholds may artificially create the impression of lateralization, maps of rCMRgl declines were displayed with an uncorrected voxelwise threshold of *p* \< .005. Nevertheless, additional information on whole-brain corrected results (FWE correction on the cluster-level; FWE~c~) is provided in the respective tables.

Detailed results of within group analyses and regression are additionally provided as supplementary information. Results of the within group one-sample *t*-tests of rCMRgl declines in MCI-AD and dementia-AD patients are reported at *p* \< .05 FWE voxel-level corrected (FWE~v~), to avoid excessive clustering and provide better information on the anatomical pattern of rCMRgl declines.

3. Results {#s0030}
==========

3.1. Subject characteristics and cognitive performance {#s0035}
------------------------------------------------------

The subject groups\' baseline characteristics are summarized in [Table 1](#t0005){ref-type="table"}, data of 24-month cognitive changes are provided as supplementary data (Table S1). No significant differences were observed for baseline age, gender distribution, education and time interval between groups. As expected, in comparison with the CU group, the dementia-AD and MCI-AD groups had a higher proportion of APOE4 carriers, lower baseline cognitive performance, and greater 24-month cognitive declines. For the sub-items of the ADAS-cog 13 at baseline (illustrated in [Fig. 1](#f0005){ref-type="fig"}), most prominent deficits were observed for memory functions \[i.e. Delayed Word Recall, Word Recall, Word Recognition (all dementia-AD\>MCI-AD\>CU) and Orientation (dementia-AD\>MCI-AD/CU)\], Processing Speed \[i.e. Number Cancellation (dementia-AD\>MCI-AD\>CU)\] and Praxis \[i.e. Construction (dementia-AD\>MCI-AD\>CU)\], while only minor deficits were evident for language functions \[i.e. Word Finding and Naming (all dementia-AD/MCI-AD\>CU\]. Similar results were seen when the respective subitems were grouped as subdomains, again with most prominent deficits in the memory subdomain (dementia-AD\>MCI-AD\>CU) and less profound deficits in the praxis and language subdomain (dementia-AD\>MCI-AD\>CU and dementia-AD/MCI-AD\>CU). During the 2 year follow up period cognitive decline again was most evident for memory functions \[i.e. Orientation (dementia-AD\>MCI-AD\>CU)\], Word Recall, Delayed Word Recall, Word Recognition (all 3 items dementia-AD/MCI-AD\>CU) and Recall Instructions (dementia-AD\>MCI-AD/CU), followed by Praxis (i.e. Ideational Praxis (dementia-AD\>MCI-AD/CU) and language functions \[i.e. Word Finding, Naming, Commands, Comprehension (all dementia-AD\>MCI-AD/CU) and Spoken Language (dementia-AD\>CU)\]. Analyses of the ADAS subdomains yielded significant decline within the memory subdomain for both AD and MCI subjects (dementia-AD\>MCI-AD\>CU) and within the language and praxis subdomain for AD subjects only (both dementia-AD\>MCI-AD/CU).Table 1Baseline subject characteristics.Table 1CU Aβ-MCI Aβ+AD Aβ+*P* value(*n* = 40)(*n* = 76)(*n* = 51)Baseline age76.1 ± 5.375.8 ± 6.875.2 ± 7.1n.s.\*Gender (M/F)20/2051/2531/20n.s.Education (years)15.5 ± 3.216.3 ± 2.85915.3 ± 3.2n.s.Timeinterval (years)1.99 ± 0.261.95 ± 0.261.84 ± 0.44n.s\*APOE E4 gene dose (NC/HT/HM)32/8/032/30/148/28/154.98E-08MMSE28.6 ± 1.526.9 ± 1.923.4 ± 1.92.09E-29CDR-SOB0.1 ± 0.21.7 ± 1.04.3 ± 1.57.80E-43AVLT-STM8.3 ± 3.33.6 ± 3.11.4 ± 1.6 (50)2.76E-22AVLT-LTM7.5 ± 3.82.1 ± 3.00.6 ± 1.54.62E-23AVLT-Total42.2 ± 9.229.4 ± 8.122.8 ± 6.8 (50)1.05E-21Category fluency (animals)19.8 ± 4.815.5 ± 3.913.3 ± 4.21.03E-10ADAS-cog 1310.1 ± 4.5 (39)20.0 ± 5.928.7 ± 7.6 (50)6.89E-29ADAS-cog 116.4 ± 3.012.1 ± 4.218.0 ± 6.06.94E-23ADAS memory subdomain (0--45)8.8 ± 4.317.0 ± 5.823.8 ± 5.97.47E-26ADAS language subdomain (0--25)0.3 ± 0.61.2 ± 1.21.4 ± 1.82.05E-04ADAS praxis subdomain (0−10)0.4 ± 0.60.7 ± 0.71.3 ± 0.81.29E-08ADAS Q1 word recall (0--10)3.0 ± 1.24.8 ± 1.26.0 ± 1.41.95E-21ADAS Q2 commands (0--5)0.1 ± 0.30.2 ± 0.50.3 ± 0.5n.s.ADAS Q3 construction (0--5)0.3 ± 0.50.6 ± 0.61.0 ± 0.71.86E-07ADAS Q4 delayed word recall (0--10)3.1 ± 1.96.7 ± 2.38.5 ± 1.73.91E-25ADAS Q5 naming (0--5)0.1 ± 0.30.3 ± 0.50.3 ± 0.50.008ADAS Q6 Ideational Praxis (0--5)0.1 ± 0.30.1 ± 0.30.2 ± 0.4\<0.05ADAS Q7 orientation (0--8)0.2 ± 0.40.5 ± 0.82.5 ± 1.77.42E-21ADAS Q8 word recognition (0−12)2.6 ± 2.44.9 ± 3.06.7 ± 3.08.41E-10ADAS Q9 recall instructions (0--5)0.0 ± 0.20.1 ± 0.40.1 ± 0.4n.s.ADAS Q10 spoken language (0--5)0.1 ± 0.20.1 ± 0.40.2 ± 0.6n.s.ADAS Q11 word finding (0--5)0.1 ± 0.20.4 ± 0.60.5 ± 0.80.004ADAS Q12 comprehension (0--5)0.0 ± 0.20.1 ± 0.30.1 ± 0.5n.s.ADAS Q14 number cancellation (0--5)0.5 ± 0.7(39)1.1 ± 0.72.2 ± 1.5 (50)1.14E-13[^2]Fig. 1Mean baseline performance (top chart) and change over 24 months (bottom chart) for the ADAS-cog 13 subitems for dementia-AD (AD), MCI-AD (MCI) and cognitively unimpaired (CU) subjects. Results are illustrated as percentage of the maximum possible value, with higher values indicating worse performance. Significant group differences are indicated by \* (ANOVA: \**p* \< .5; \*\**p* \< .001; \*\*\**p* \< .0001; for detailed *p*-values see [Table 1](#t0005){ref-type="table"} and Table S1) with the corresponding between group differences below in brackets (i.e. Duncan\'s multiple range test).Fig. 1

For Category Fluency (animals) significant deficits were found at baseline for dementia-AD and MCI-AD (dementia-AD\>MCI-AD\>CU) with weakly significant 24-month decline (dementia-AD/MCI-AD\>CU).

3.2. 24-month rCMRgl declines {#s0040}
-----------------------------

Compared to CU, MCI-AD patients showed rCMRgl declines predominantly located within the left lateral temporal cortex (pFWE~c~ \< 0.05) (see [Fig. 2](#f0010){ref-type="fig"} and [Table 2](#t0010){ref-type="table"}). This pattern of rCMRgl decline was found to be strongly left lateralized (LIwm 0.78).Fig. 2T-score maps (*p* \< .005 uncorrected) of greater 24-month rCMRgl declines in amyloid-β positive MCI-AD patients compared to amyloid-β negative cognitively unimpaired controls (CU) with the corresponding histogram of bootstrapped lateralization indices (LIs).Fig. 2Table 224-month rCMRgl declines in amyloid-β positive MCI-AD patients compared to amyloid-β negative cognitively unimpaired controls.Table 2**Region*k*p(unc)MNI (mm)xyzLInferior Temporal Gyrus13627.95E-06**[†](#tf0010){ref-type="table-fn"}**−64−32−18**LMiddle Temporal Gyrus2.11E-05−60−46−14LInferior Temporal Gyrus0.0002−58−64−8**LMiddle Temporal Gyrus22006.47E-05**[⁎](#tf0005){ref-type="table-fn"}**−52−6822**LSuperior Parietal Lobule0.0001−38−6450LPrecuneus0.0003−34−7842**LParahippocampal Gyrus1610.0004−38−22−30LPrecuneus1590.0014−6−5034**LPrecuneus0.0025−4−6434LCingulate Gyrus0.00400−3234[^3][^4][^5]

Subjects with dementia-AD in comparison to CU exhibited bilateral declines of rCMRgl (see [Fig. 3](#f0015){ref-type="fig"} and [Table 3](#t0015){ref-type="table"}), predominantly within the temporal cortices (lateral\>medial), the parietal lobes (i.e. bilateral inferior parietal lobule), precuneus and the posterior cingulate (all pFWE~c~ \< 0.05) with signs of weak right hemispheric lateralization (LIwm −0.33).Fig. 3T-score maps (p \< .005 uncorrected) of greater 24-month rCMRgl declines in amyloid-β positive dementia-AD patients compared to amyloid-β negative cognitively unimpaired controls (CU) with the corresponding histogram of bootstrapped lateralization indices (LIs).Fig. 3Table 324-month rCMRgl declines in amyloid-β positive dementia-AD patients compared to amyloid-β negative cognitively unimpaired controls.Table 3**Region*k*p(unc)MNI (mm)xyzRInferior Parietal Lobule11,2253.51E-07**[⁎](#tf0015){ref-type="table-fn"}**58−5052**RInferior Parietal Lobule4.39E-0752−5652RInferior Temporal Gyrus8.30E-0758−48−14**LMiddle Temporal Gyrus68459.79E-07**[⁎](#tf0015){ref-type="table-fn"}**−62−46−14**LInferior Parietal Lobule1.74E-06−60−4448LMiddle Temporal Gyrus6.41E-06−52−7022**LPrecuneus40675.15E-06**[⁎](#tf0015){ref-type="table-fn"}**0−6844**LCingulate Gyrus5.64E-06−2−3430LPrecuneus0.0002−6−4634**LCaudate1250.0003−10108LMiddle Frontal Gyrus3470.0009−262860**LSuperior Frontal Gyrus0.0014−161076LMiddle Frontal Gyrus0.0004−301464**RMiddle Frontal Gyrus4600.0006381264**RMiddle Frontal Gyrus0.000744466[^6][^7]

Additional comparisons of dementia-AD patients with MCI-AD patients yielded stronger and predominant right hemispheric rCMRgl declines in dementia-AD patients (see [Fig. 4](#f0020){ref-type="fig"} and [Table 4](#t0020){ref-type="table"}), mostly within the right temporal cortex (lateral\>medial), the parietal lobe, precuneus, the posterior cingulate (one cluster, pFWE~c~ \< 0.05) and the right frontal lobe (pFWE~c~ \< 0.05). This pattern of rCMRgl decline was found to be strongly right lateralized (LIwm −0.79).Fig. 4T-score maps (p \< .005 uncorrected) of greater 24-month rCMRgl declines in amyloid-β positive dementia-AD patients compared to amyloid-β positive MCI-AD patients with the corresponding histogram of bootstrapped lateralization indices (LIs).Fig. 4Table 424-month rCMRgl declines in amyloid-β positive dementia-AD patients compared to amyloid-β positive MCI-AD patients.Table 4**Region*k*p(unc)MNI (mm)xyzRMiddle Temporal Gyrus15,7322.70E-06**[⁎](#tf0020){ref-type="table-fn"}**46−6010**RInferior Parietal Lobule4.17E-0668−3446RInferior Parietal Lobule5.82E-0660−4046**LSuperior Frontal Gyrus8320.0001−24674**LMiddle Frontal Gyrus0.0003−302460LMiddle Frontal Gyrus0.0010−243256**RSuperior Frontal Gyrus19730.0002**[⁎](#tf0020){ref-type="table-fn"}**181674**RMiddle Frontal Gyrus0.0005381854RMiddle Frontal Gyrus0.0007302650**RSuperior Frontal Gyrus4450.00022664−22**RMiddle Frontal Gyrus0.00084048−22RMiddle Frontal Gyrus0.00173864−2**LMiddle Frontal Gyrus1810.0002−563026RSubgyral White Matter1440.0004422420LSupramarginal Gyrus2190.0005−62−6040**[^8][^9]

Within-group analyses yielded rCMRgl declines (pFWE~v~ \< 0.05) in MCI-AD and dementia-AD, most prominently within the (posterior) cingulate, the bilateral temporal and parietal lobes and the precuneus with signs of weak left hemispheric lateralization for MCI-AD and weak right hemispheric lateralization for dementia-AD (MCI-AD: LIwm 0.46; dementia-AD: LIwm −0.44). rCMRgl declines were also observed in CU subjects, yet less extended and in differing regions (i.e. mostly within frontal and insular cortex and subcortical stuctures; all pFWE~c~ \< 0.05) with signs of weak right hemispheric lateralization (CU: LIwm −0.48). Additional information on within-group analyses is provided as supplementary material (i.e. Table S1--3; Fig. S1--3).

3.3. Associations of 24-month rCMRgl declines with cognitive decline {#s0045}
--------------------------------------------------------------------

Post-hoc regression analyses showed that cognitive worsening as measured by the ADAS-cog 13 was associated (pFWE~c~ \< 0.05) with rCMRgl declines within the left lateral temporal cortex in MCI-AD. This pattern was found to be strongly left lateralized (LIwm 0.89). In dementia-AD subjects, cognitive worsening was associated with bilateral rCMRgl declines predominantly within the bilateral parietal lobule, precuneus and the posterior cingulate (one large cluster at pFWE~c~ \< 0.05) with signs of weak right hemispheric lateralization (LIwm −0.28). Due to missing values in the dementia-AD group (*N* = 4) of Q14 (i.e. number cancellation) of the ADAS-cog 13 additional regression analyses were done with complete data of the ADAS-cog 11 where the same pattern of associations was found (data not shown), similarly with signs of weak right hemispheric lateralization (LIwm −0.33).

Declines of verbal fluency \[i.e. Category Fluency (animals)\] did not show any significant associations with rCMRgl declines in MCI-AD subjects (all *p* \> .6 FWE~c~). Uncorrected associations (*p* \< .005) were mainly located within the left basal ganglia next to a smaller cluster within the left temporal cortex, overall with signs of strong left lateralization (LIwm = 0.7).

In dementia-AD subjects however, declines of verbal fluency showed significant associations (*p* \< .05 FWE~c~) with rCMRgl declines within the left precuneus and parietal lobule, the left temporal and frontal cortex. This pattern was found to be strongly left lateralized (LIwm = 0.7). Additional information on regression analyses is provided as supplementary material (i.e. Table S5--6; Fig. S4--6).

4. Discussion {#s0050}
=============

To our knowledge, this is the first longitudinal FDG PET study to investigate asymmetric patterns of rCMRgl decline in MCI and early dementia stages of AD. In a well characterized sample of patients we observed diverging patterns of asymmetric and/or lateralized rCMRgl declines in Aβ + MCI-AD and dementia-AD patients compared to Aβ- cognitively unimpaired controls (CU). While -- in comparison to CU - MCI-AD subjects yielded signs of strong left hemispheric lateralization, early stages of dementia-AD were associated with right hemispheric lateralization of rCMRgl, even though this effect was found to be weaker as compared to MCI-AD patients. Consequently, rCMRgl declines in dementia-AD patients compared to MCI-AD patients were found to be strongly right lateralized. Similar directionalities of lateralization were found for within-group analyses of rCMRgl declines in MCI-AD and dementia-AD, however in MCI-AD patients left hemispheric lateralization was weaker as when compared to CU, which in turn showed rCMRgl declines of predominantly prefrontal brain regions with signs of weak right hemispheric lateralization. Importantly, the pattern of rCMRgl declines we observed in MCI-AD and dementia-AD subjects was restricted to brain regions typically affected in AD, thus closely resembling previous FDG-PET studies (e.g. [@bb0180]). Although the estimation of lateralization with the LI-Toolbox implies the use of a priori unthresholded imaging data, rCMRgl declines within AD typical regions did reach statistical significance after correction for multiple comparisons, thus providing additional statistical validation.

Additional analyses of cognitive data furthermore showed predominant decline of memory functions for ADAS-cog subitems and subdomains. Importantly, no significant decline of the language subdomain was found for MCI-AD subjects. Post-hoc regression analyses of the 24-month ADAS-cog changes furthermore yielded strong left hemispheric lateralization of its associations with rCMRgl decline. On the other hand, significant decline was found for tests of verbal fluency \[i.e. Category fluency (animals)\] and results of regression analyses were strongly left lateralized in both dementia-AD and MCI-AD.

FDG PET measurements of rCMRgl have been used in the detection, tracking and differential diagnosis of AD and can be observed long before clinical onset of AD ([@bb0180]). Presumed pathophysiological underpinnings of rCMRgl reductions in AD include neuronal and glial derangements of mitochondrial and metabolic functions and consecutive reductions in synaptic function and density ([@bb0145]). In contrast, earlier upstream pathophysiological events such as amyloid deposition may have plateaued even before clinical signs of AD are noticeable ([@bb0085]). Consequently, FDG PET may be more reflective of the clinical course of AD. Importantly, reductions in rCMRgl are sought to precede brain atrophy and alterations in glucose metabolism cannot be solely explained by brain atrophy and increases in CSF spaces ([@bb0080]; [@bb0085]).

Within the past decades the question whether AD pathology develops in an asymmetric or lateralized fashion has been investigated by numerous studies, yet with conflicting results. While post-mortem studies yielded a high variability of AD pathology for the left and right hemisphere, no clear signs of asymmetry or lateralization were observed ([@bb0105]; [@bb0250]). In contrast, PET measurements of amyloid deposition in MCI and AD patients were found to be weakly left lateralized for some brain regions in MCI and right lateralized in AD, somewhat similar to the pattern of rCMRgl declines we observed in our within-group analyses ([@bb0175]). It has to be noted though that these observations were made in a small sample and still require additional confirmation by further studies.

Earlier studies of brain metabolism in AD and subjects at high risk for AD showed asymmetric reductions in cerebral glucose uptake, in parts with predominant left hemispheric metabolic deficits ([@bb0040]; [@bb0120]; [@bb0215]; [@bb0220]) while asymmetric glucose metabolism was found to correlate with cognitive dysfunction of lateralized domains such as language (i.e. left hemisphere) or visuospatial processing (i.e. right hemisphere) ([@bb0065]). Similar observations had been made by Keilp et al. with differing correlations of left and right hemispheric perfusion deficits with specific cognitive domains in AD ([@bb0115]). In addition, more recent studies found marked left hemispheric decrements in FDG uptake in AD patients ([@bb0240]). Consideration of hemispheric differences in AD has also been given in brain structural studies. Observations of accentuated left ventricular enlargement in early AD were -- in parts -- confirmed by more sophisticated analyses of brain morphometry with detailed characterization of the spatial dynamics of brain atrophy in AD. Here, affirmative to studies of brain metabolism, asymmetric patterns of gray matter loss in AD with a left hemispheric pronunciation were demonstrated ([@bb0100]; [@bb0230], [@bb0235]). Specific focus has also been given to the hippocampus with meta-analyses showing a consistent left-less-than-right hippocampal volume in MCI and AD patients but also control subjects. While effect sizes were the strongest in MCI subjects, these results indicate dynamic changes of physiological asymmetry patterns during the course of the disease ([@bb0210]). On the other hand, Derflinger et al. argued that findings of left lateralized AD pathology are mainly attributable to a selection bias introduced by largely language based cognitive assessments ([@bb0030]). In our sample post-hoc regression analyses showed that 24-month cognitive decline (ADAS-cog) was significantly associated with rCMRgl decline in both dementia-AD and MCI-AD subjects with patterns closely resembling the results from our group comparisons. Whereas for dementia-AD subjects bilateral decline with at most weak right hemispheric lateralization was seen, evidence of strong left hemispheric lateralization was found for associations of cognitive decline with rCMRgl declines in MCI-AD patients. For both MCI and AD subjects cognitive deficits at baseline and longitudinal decline of the ADAS-cog subitems were most pronounced in tests representative of memory performance, processing speed and praxis while language functions were only modestly affected at baseline and decline was only evident in dementia-AD but not MCI-AD patients, overall consistent with ADNI\'s focus on memory impairment ([@bb0165]). Similar results were obtained when subitems were grouped to subdomains (i.e. memory, language, praxis), again without significant decline of the language subdomain in MCI-AD subjects. While ADAS-cog provides a general measure of cognitive function we additionally analyzed Category Fluency (animals), a more language focused cognitive assessment of semantic fluency, with known left lateralization in healthy subjects as well as AD patients ([@bb0060]; [@bb0130]; [@bb0260]; [@bb0265]). Here, we did find weak but significant 24-month decline in both dementia-AD and MCI-AD with regression analyses yielding strong left hemispheric lateralization for the respective associations with rCMRgl decline, confirmatory to previous reports ([@bb0265]). Nevertheless, in MCI-AD subjects, these associations did not reach statistical significance (all *p* \> .6 FWE~c~) with the largest cluster located within subcortical structures (i.e. caudate nucleus).

Overall, these findings suggest that left hemispheric rCMRgl declines in our sample of MCI-AD subjects are not the primary result of a selection bias due to earlier detection of language impairment and/or predominant decline of language functions.

Thus far, no clear-cut explanation or potential mechanism has been provided for why left hemispheric brain regions could be more susceptible towards AD related neurodegeneration. Strong evidence indicates that brain regions associated with the default mode network (DMN) -- a network of distinct brain regions characterized by increased activity under resting conditions -- are particularly affected by AD pathology ([@bb0055]).

This in turn lead to the hypothesis that acquired lifetime cerebral metabolism of DMN regions facilitates AD related pathophysiological mechanisms, thus providing a potential explanation for the selective neuronal vulnerability that is seen in AD ([@bb0015]). Indeed, earliest Aβ accumulation appears to manifest mainly within medial brain regions that form part of the DMN, while later stages of Aβ accumulation include large parts of the neocortex ([@bb0155]). Brain regions of the DMN -- next to others -- include the PCC, precuneus as well as lateral and medial temporal lobe structures. Intriguingly, two studies focusing on the lateralization of DMN activity in healthy subjects showed left hemispheric lateralization, potentially supporting our and previous observations of left lateralized pathology in MCI ([@bb0005]; [@bb0225]). However, AD seems to be characterized by diverging trajectories of regional Aβ pathology and brain metabolic declines ([@bb0160]) and although DMN alterations are well established in AD ([@bb0170]), it still remains to be clarified whether these changes develop in an asymmetric or even lateralized manner. Hence further research is required to shed light on the intricate interplay of pathophysiological processes that may lead to a potentially lateralized selective neuronal vulnerability in AD.

Potential support for a higher left hemispheric susceptibility towards AD related neurodegeneration may also be provided by the logopenic variant of primary progressive aphasia (lpPPA), a focal variant of AD with typical AD pathology and distinct patterns of left lateralized temporoparietal atrophy and hypometabolism ([@bb0045]; [@bb0050]; [@bb0070]; [@bb0125]; [@bb0190]). Of note though, other focal variants such as the posterior cortical atrophy exist, that do not present with obvious lateralized pathological hallmarks ([@bb0150]).

Somewhat contrasting, we found weak respectively strong right hemispheric lateralization in AD patients when compared to healthy controls and MCI-AD patients, indicating that metabolic differences between hemispheres develop in a dynamic fashion and seem to diminish with further progression of the disease. This discrepancy needs to be interpreted under consideration of current theories on mechanisms related to disease progression. Both animal and human research support the concept of AD pathology spreading via neuronal transport and transsynaptic diffusion within interconnected brain regions (such as the DMN) which -- in theory- would allow for interhemispheric spreading of to begin with more lateralized pathological changes such as Aβ deposition and TAU formation ([@bb0110]; [@bb0245]).

Several limitations of our study need to be acknowledged. First, this is an exploratory study of preexisting data. However, this limitation is compensated for by the detailed characterization of patients and controls of the ADNI cohort, its comparably large sample sizes and the longitudinal data. We also acknowledge the fact that evidence for strong left hemispheric lateralization was only seen in MCI-AD patients when compared to CU, while within group analyses showed same-directional but weaker effects. Nevertheless, comparisons against control subjects are mandatory as over time rCMRgl declines in healthy subjects as well and hence needs to be controlled for in order to distinguish AD related pathology from effects related to normal aging ([@bb0010]). In this context we also want to stress that by the inclusion of exclusively MCI and AD patients with, and control subjects without evidence of Aβ pathology high specificity of our findings with respect to AD as probable cause is ensured. However, as Aβ pathology was determined based on availability of CSF measures or AV-45 PET imaging data, additional analyses to investigate the relationship between regional amyloid burden and rCMRgl declines in the context of hemispheric lateralization were not feasible in this sample, a question that should be addressed by future studies.

5. Conclusion {#s0055}
=============

We found left lateralized 24-month rCMRgl declines in Aβ positive persons with MCI, which are not apparent in the dementia stages of AD. It remains to be clarified whether this decline reflects preferential vulnerability to the early stages of AD or neurodegenerative patterns that account for the clinical (e.g. verbal memory) features of MCI.
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[^1]: Data used in preparation of this article were obtained from the Alzheimer\'s Disease Neuroimaging Initiative (ADNI) database ([adni.loni.usc.edu](http://adni.loni.usc.edu){#ir0005}). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at <http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf>.

[^2]: Data is presented as mean ± SD except for \*.Group differences were assessed by ANOVA except for \* (i.e. Chi-squared test); *NC* noncarriers; *HT* heterozygotes; *HM* homozygotes; *ADAS-cog* Alzheimer\'s Disease Assessment Scale-cognitive subscale; *MMSE* Mini-Mental State Examination; *CDR-SOB* Clinical Dementia Rating Scale Sum of Boxes; *AVLT* Auditory Verbal Learning Test; *STM* short term memory; *LTM* long term memory.

[^3]: Results are listed at p \< .005 uncorrected and a cluster size threshold of 100 continuous voxels. Bold data indicate primary peaks within a cluster, non-bold data indicate secondary peaks within the cluster. MNI: Montreal Neurological Institute; p(unc): uncorrected p-value; k: cluster size.

[^4]: *p* \< .05 FWE corrected on the cluster-level.

[^5]: *p* \< .1 FWE corrected on the cluster-level.

[^6]: Results are listed at p \< .005 uncorrected and a cluster size threshold of 100 continuous voxels. Bold data indicate primary peaks within a cluster, non-bold data indicate secondary peaks within the cluster. *MNI*: Montreal Neurological Institute; *p(unc)*: uncorrected p-value; *k*: cluster size.

[^7]: *p* \< .05 FWE corrected on the cluster-level.

[^8]: Results are listed at p \< .005 uncorrected and a cluster size threshold of 100 continuous voxels. Bold data indicate primary peaks within a cluster, non-bold data indicate secondary peaks within the cluster. *MNI*: Montreal Neurological Institute; *p(unc)*: uncorrected p-value; *k*: cluster size.

[^9]: *p* \< .05 FWE corrected on the cluster-level.
